Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy

Molecular Pharmaceutics

Volumn 9, Issue 6, 2012, Pages 1590-1598

  Zhang, Pengcheng ^a   Hu, Luojuan ^a   Yin, Qi ^a   Feng, Linyin ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

blood brain barrier; glioma; micelle; sequential targeting

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; INTEGRIN; PACLITAXEL; SODIUM CHLORIDE; TRANSFERRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; ENDOCYTOSIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYBRID CELL; IN VITRO STUDY; MALE; MICELLE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL TIME; WEIGHT REDUCTION;

ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE; CELL LINE, TUMOR; GLIOMA; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICELLES; MODELS, BIOLOGICAL; NANOMEDICINE; OLIGOPEPTIDES; PACLITAXEL; RATS, SPRAGUE-DAWLEY; TRANSFERRIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862015950     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200600t     Document Type: Article

References (38)

1. Mangiola, A.; Anile, C.; Pompucci, A.; Capone, G.; Rigante, L.; De Bonis, P. Glioblastoma therapy: going beyond Hercules Columns. Expert Rev. Neurother. 2010, 10, 507-514.
2. Chamberlain, M. C. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev. Neurother. 2010, 10, 1537-1544.
3. deVries, N. A.; Beijnen, J. H.; Boogerd, W.; van Tellingen, O Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev. Neurother. 2006, 6, 1199-1209.
4. Fidler, I. J.; Yano, S.; Zhang, R. D.; Fujimaki, T.; Bacana, C. D. The seed and soil hypothesis: vascularisation and brain metastasis. Lancet Oncol. 2002, 3, 53-57.
5. Yang, H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res. 2010, 27, 1759-1771.
6. Du, J.; Lu, W. L.; Ying, X.; Liu, Y.; Du, P.; Tian, W.; Men, Y.; Guo, J.; Zhang, Y.; Li, R. J.; Zhou, J.; Lou, J. N.; Wang, J. C.; Zhang, X.; Zhang, Q. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol. Pharmaceutics 2009, 6, 905-917.
7. Xin, H. L.; Jiang, X. Y.; Gu, J. J.; Sha, X. Y.; Chen, L. C.; Law, K.; Chen, Y.; Wang, X.; Jiang, Y.; Fang, X Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011, 32, 4293-4305.
8. Pang, Z. Q.; Feng, L.; Hua, R. R.; Chen, J.; Gao, H. L.; Pan, S. Q.; Jiang, X.; Zhang, P. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol. Pharmaceutics 2010, 7, 1995-2005.
9. Wang, B. Sialic acid is an essential nutrient for brain development and cognition. Annu. Rev. Nutr. 2009, 29, 177-222.
10. Bu, G. J.; Maksymovitch, E. A.; Nerbonne, J. M.; Schwartz, A. L. Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. J. Biol. Chem. 1994, 269, 18521-18528. (Pubitemid 24224088)
11. Knisely, J. M.; Lee, J.; Bu, G. Measurement of receptor endocytosis and recycling. Methods Mol. Biol. 2008, 457, 319-332.
12. Lucas, M. R. The impact of chemo brain on the patient with a high-grade glioma. Adv. Exp. Med. Biol. 2010, 678, 21-25.
13. Jones, A. R.; Shusta, E. .V Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 2007, 24, 1759-1771. (Pubitemid 47206625)
14. Poduslo, J. F.; Curran, G. L.; Berg, C. T. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 5705-5709. (Pubitemid 24174397)
15. Desgrosellier, J. S.; Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10, 9-22.
16. MacDonald, T. J.; Taga, T.; Shimada, H.; Tabrizi, P.; Zlokovic, B. V.; Cheresh, D. A.; Laug, W. E. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha v integrin antagonist. Neurosurgery 2001, 48, 151-157. (Pubitemid 32039837)
17. Zhang, P. C.; Hu, L. J.; Wang, Y. C.; Wang, J.; Feng, L. Y.; Li, Y. P. Poly(ε-caprolactone)-block-poly(ethyl ethylene phosphate) micelles for brain-targeting drug delivery: in vitro and in vivo valuation. Pharm. Res. 2010, 27, 2657-2669.
18. Pang, Z. Q.; Lu, W.; Gao, H. L.; Hu, K. L.; Chen, J.; Zhang, C. L.; Gao, X.; Jiang, X.; Zhu, C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Controlled Release 2008, 128, 120-127.
19. Deutsch, H. M.; Glinksi, J. A.; Hernandez, M.; Haugwitz, R. D.; Narayanan, V. L.; Suffness, M.; Zalkow, L. H. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of PTX with potent antitumor activity. J. Med. Chem. 1989, 32, 788-792. (Pubitemid 19100192)
20. Lu, W.; Zhang, Y.; Tan, Y. Z.; Hu, K. L.; Jiang, X. G.; Fu, S. K. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J. Controlled Release 2005, 107, 428-448.
21. Cho, Y. W.; Lee, J.; Lee, S. C.; Hun, K. M.; Park, K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J. Controlled Release 2004, 97, 249-257. (Pubitemid 38759482)
22. Chen, H.; Hu, X.; Zhang, Y.; Li, D.; Wu, Z.; Zhang, T. Effect of chain density and conformation on protein adsorption at PEG-grafted polyurethane surfaces. Colloid Surf., B 2008, 61, 237-243.
23. Vesterberg, O.; Breig, U. Quantitative analysis of multiple molecular forms of transferrin using isoelectric focusing and zone immunoelectrophoresis assay (ZIA). J. Immunol. Methods 1981, 46, 53-62. (Pubitemid 11010945)
24. Grant, B. D.; Donaldson, J. G. Pathways and mechanisms of endocytic recycling. Nat. Rev. Mol. Cell Biol. 2009, 10, 597-608.
25. Rejman, J.; Bragonzi, A.; Conese, M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol. Ther. 2005, 12, 468-474. (Pubitemid 41150132)
26. Skuli, N.; Monferran, S.; Delmas, C.; Favre, G.; Bonnet, J.; Toulas, C.; Cohen-Jonathan, M. E Alphavbeta3/alphavbeta5 integrins- FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res. 2009, 69, 3308-3316.
27. Taherian, A.; Li, X.; Liu, Y.; Haas, T. A. Differences in integrin expression and signaling within human breast cancer cells. BMC Cancer 2011, 11, 293.
28. Karmakar, S.; Banik, N. L.; Ray, S. K. Current Endeavors for Enhancing Efficacy of Paclitaxel for Treatment of Glioblastoma. In Glioblastoma; Ray, S. K., Ed; Springer Inc.: New York, 2010; pp 299-323.
29. D'Abaco, G. M.; Kaye, A. H. Integrins: molecular determinants of glioma invasion. J. Clin. Neurosci. 2007, 14, 1041-1048. (Pubitemid 47588943)
30. Zhang, X.; Zheng, X.; Jiang, F.; Zhang, Z. G.; Katakowski, M.; Chopp, M. Dual-color fluorescence imaging in a nude mouse orthotopicglioma model. J. Neurosci. Methods 2009, 181, 178-185.
31. Zakharova, V. M.; Serpi, M.; Krylov, I. S.; Peterson, L. W.; Breitenbach, J. M.; Borysko, K. Z.; Drach, J. C.; Collins, M.; Hilfinger, J. M.; Kashemirov, B. A.; McKenna, C. E. Tyrosine-based 1-(S)-[3- hydroxy-2-(phosphonomethoxy) propyl]cytosine and -adenine ((S)- HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. J. Med. Chem. 2011, 54, 5680-5693.
32. Beaumont, K.; Webster, R.; Gardner, I.; Dack, K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr. Drug Metab. 2003, 4, 461-485. (Pubitemid 37540382)
33. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-60. (Pubitemid 350223348)
34. Cho, Y. W.; Lee, J.; Lee, S. C.; Hun, K. M.; Park, K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J. Controlled Release 2004, 97, 249-257. (Pubitemid 38759482)
35. Rice, A.; Liu, Y.; Michaelis, M. L.; Himes, R. H.; Georg, G. I.; Audus, K. L. Chemical modification of paclitaxel (Taxol) reduces Pglycoprotein interactions and increases permeation across the bloodbrain barrier in vitro and in situ. J. Med. Chem. 2005, 48, 832-838. (Pubitemid 40209105)
36. Wang, X. H.; Zhao, G.; Van, S.; Jiang, N.; Yu, L.; Vera, D.; Howell, S. B. Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother. Pharmacol. 2010, 65, 515-526.
37. Ke, X. Y.; Zhao, B. J.; Zhao, X.; Wang, Y.; Chen, X. M.; Zhao, B. X.; Zhao, S. S.; Zhang, X.; Zhang, Q. The therapeutic efficacy of conjugated linoleic acid-paclitaxel on glioma in the rat. Biomaterials. 2010, 31, 5585-5564.
38. Sparreboom, A.; Scripture, C. D.; Trieu, V.; Williams, P. J.; De, T.; Yang, A.; Beals, B.; Figg, W. D.; Hawkins, M.; Desai, N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 2005, 11, 4136-4143. (Pubitemid 40791578)